Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies.

Patients with hematologic diseases receiving anti-CD20 monoclonal antibodies show a low seroconversion rate after two doses of mRNA Coronavirus disease-2019 (COVID-19) vaccines, especially within 12 months of their last anti-CD20 antibodies [[1]]. In total, while either humoral or cellular responses were identified in 22 (42%) patients after two doses of the vaccine, a third vaccination induced them in 36 (72%) patients (Fig. Ten patients were excluded from the final analysis: four patients were infected with SARS-CoV-2 before the completion of blood sampling, two patients had undocumented COVID-19 infection, two did not have blood sampling before the third vaccination, and two did not receive their third dose. [Extracted from the article]